Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast
commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare
diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal
complement, a group of proteins that play an important role in the body's immune response and can destroy healthy tissue in certain patients.
Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor.
Today, Soliris is approved in more than 40 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH),
and in the United States and European Union as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Soliris is not indicated for the treatment of patients with Shiga toxin E coli-related hemolytic uremic syndrome (STEC-HUS). Alexion is working urgently
to investigate Soliris and additional product candidates as treatments for patients with other rare and severe diseases.